The objective of this study is to evaluate the effectiveness and safety of Tripterygium glycosides combined with glucocorticoids for the treatment of refractory nephrotic syndrome(NS).Computer search of Chinese and En...The objective of this study is to evaluate the effectiveness and safety of Tripterygium glycosides combined with glucocorticoids for the treatment of refractory nephrotic syndrome(NS).Computer search of Chinese and English databases,including CNKI,VIP,Wan Fang Database,PubMed,Cochrane Library,Embase,and Sinomed,for randomized controlled trials(RCTs)of Tripterygium glycosides combined with glucocorticoids for refractory NS(RNS)was conducted.Meta-analysis was performed using RevMan5.3.Thirteen RCTs comprising 994 patients were included in the study.Tripterygium glycosides combined with glucocorticoids had a statistical significance on the effective rate(odds ratio[OR]=4.69,95%confidence interval[CI]3.29,6.67,P<0.00001),24-h urine protein(Weighted mean difference(MD)=-0.57,95%CI[-0.62,-0.51],P<0.00001),serum albumin(MD=4.77,95%CI[4.30,5.24],P<0.00001),total serum protein(MD=9.45,95%CI[8.73,10.17],P<0.00001),urea nitrogen(MD=-0.53,95%CI[-0.90,-0.17],P=0.005),and serum creatinine(MD=-8.45,95%CI[-15.32,-1.57],P=0.02).There was no statistical significance on adverse reactions(OR=0.68,95%CI[0.41,1.12],P=0.13).Tripterygium glycosides combined with glucocorticoids could improve clinical effective rate,reduce 24-h urine protein,improve serum albumin and total serum protein,and reduce urea nitrogen and serum creatinine levels in patients with RNS.However,the quality of the included literature is poor,and conclusion still needs further verification using larger samples and high-quality randomized,double-blind controlled trials.展开更多
To systematically evaluate the efficacy of urinary granules combined with RAAS system blockers in the treatment of diabetic nephropathy(DN).A meta-analysis of the data required in the literature in accordance with thi...To systematically evaluate the efficacy of urinary granules combined with RAAS system blockers in the treatment of diabetic nephropathy(DN).A meta-analysis of the data required in the literature in accordance with this study was performed using Rev Man 5.3 software.Fifteen randomized controlled trials were analyzed in the present study to evaluate the clinical effect of Niaoduqing-angiotensin converting enzyme inhibitors/angiotensin receptor blocker(ACEI/ARB)in DN patients.A total of 1063 patients were involved,including 538 patients receiving the combination treatment and 525 patients in the control group.The results showed that the clinical efficacy of Niaoduqing granule combined with ACEI/ARB was significantly better than of the control group(odds ratio=2.92,95%confidence interval[CI]1.76–4.86).The treatment combined with Niaoduqing granule decreased the 24-h urinary protein quantitation(mean difference[MD]0.71,95%CI 0.28–1.14)and urine albumin excretion rate(UAER)(MD 41.13,95%CI 26.66–55.59)levels.However,the combination group had no treatment advantage on reducing serumurea nitrogen(MD 0.86,95%CI 0.05–1.68,P=0.02)and fasting blood glucose(MD-0.03,95%CI-0.15–0.09,P=0.61).And there was no significance in adverse events between two groups(risk ratio=2.34,95%CI 0.69–7.95,P=0.17).Niaoduqing granule-ACEI/ARB combination group maybe as safe as ACEI/ARB alone,and the combination played an advantage in improvement in total effective rate,reduction of 24-h urinary protein quantitation and UAER.展开更多
Background:The global outbreak of coronavirus disease 2019(COVID-19)has brought disastrous consequences to public health and medical systems,whereas no approved medications are currently available.Benefits of traditio...Background:The global outbreak of coronavirus disease 2019(COVID-19)has brought disastrous consequences to public health and medical systems,whereas no approved medications are currently available.Benefits of traditional Chinese medicine(TCM)against COVID-19 have been observed,however,the underlying mechanistic actions remain unclarified.Due to high pathogenicity and infectivity of the new coronavirus(severe acute respiratory syndrome coronavirus 2[SARS-CoV-2]),the lack of access to SARS-CoV-2 and biosafety level 3(P3)facilities has impeded scientific investigations of TCM against COVID-19.Though low-pathogenic coronavirus and pseudoviral systems have been applied to substitute SARS-CoV-2 in fundamental studies,both models cannot imitate virological and clinical features associated with SARS-CoV-2.The virus-like particle(VLP)is a virological model that is safe and could be performed without biosafety protections.Aims and Objectives:To construct VLP of SARS-CoV-2 containing structural proteins of authentic viruses and resembling the morphology,partial life cycle,and immunoreactions of natural virions,and to introduce VLP into Chinese medical research.Materials and Methods:Using mammalian expression system,we have currently constructed SARS-CoV-2 VLP containing four essential structural proteins.Results:Based on this model,we propose six aspects of research that could be carried out for TCM formulas in the fight against COVID-19.Conclusion:Application of the VLP model provides a safe methodology to strengthen the response systems of Chinese medicine in preventing and controlling newly identified infectious diseases and offers collaborative opportunities for interdisciplinary deciphering of molecular and biological basis of anti-viral TCM formulas.展开更多
基金National Nature Fund Youth funding Project(81603570)。
文摘The objective of this study is to evaluate the effectiveness and safety of Tripterygium glycosides combined with glucocorticoids for the treatment of refractory nephrotic syndrome(NS).Computer search of Chinese and English databases,including CNKI,VIP,Wan Fang Database,PubMed,Cochrane Library,Embase,and Sinomed,for randomized controlled trials(RCTs)of Tripterygium glycosides combined with glucocorticoids for refractory NS(RNS)was conducted.Meta-analysis was performed using RevMan5.3.Thirteen RCTs comprising 994 patients were included in the study.Tripterygium glycosides combined with glucocorticoids had a statistical significance on the effective rate(odds ratio[OR]=4.69,95%confidence interval[CI]3.29,6.67,P<0.00001),24-h urine protein(Weighted mean difference(MD)=-0.57,95%CI[-0.62,-0.51],P<0.00001),serum albumin(MD=4.77,95%CI[4.30,5.24],P<0.00001),total serum protein(MD=9.45,95%CI[8.73,10.17],P<0.00001),urea nitrogen(MD=-0.53,95%CI[-0.90,-0.17],P=0.005),and serum creatinine(MD=-8.45,95%CI[-15.32,-1.57],P=0.02).There was no statistical significance on adverse reactions(OR=0.68,95%CI[0.41,1.12],P=0.13).Tripterygium glycosides combined with glucocorticoids could improve clinical effective rate,reduce 24-h urine protein,improve serum albumin and total serum protein,and reduce urea nitrogen and serum creatinine levels in patients with RNS.However,the quality of the included literature is poor,and conclusion still needs further verification using larger samples and high-quality randomized,double-blind controlled trials.
基金supported by the National Natural Science Foundation Project of China (youth science fund project. 81603570)
文摘To systematically evaluate the efficacy of urinary granules combined with RAAS system blockers in the treatment of diabetic nephropathy(DN).A meta-analysis of the data required in the literature in accordance with this study was performed using Rev Man 5.3 software.Fifteen randomized controlled trials were analyzed in the present study to evaluate the clinical effect of Niaoduqing-angiotensin converting enzyme inhibitors/angiotensin receptor blocker(ACEI/ARB)in DN patients.A total of 1063 patients were involved,including 538 patients receiving the combination treatment and 525 patients in the control group.The results showed that the clinical efficacy of Niaoduqing granule combined with ACEI/ARB was significantly better than of the control group(odds ratio=2.92,95%confidence interval[CI]1.76–4.86).The treatment combined with Niaoduqing granule decreased the 24-h urinary protein quantitation(mean difference[MD]0.71,95%CI 0.28–1.14)and urine albumin excretion rate(UAER)(MD 41.13,95%CI 26.66–55.59)levels.However,the combination group had no treatment advantage on reducing serumurea nitrogen(MD 0.86,95%CI 0.05–1.68,P=0.02)and fasting blood glucose(MD-0.03,95%CI-0.15–0.09,P=0.61).And there was no significance in adverse events between two groups(risk ratio=2.34,95%CI 0.69–7.95,P=0.17).Niaoduqing granule-ACEI/ARB combination group maybe as safe as ACEI/ARB alone,and the combination played an advantage in improvement in total effective rate,reduction of 24-h urinary protein quantitation and UAER.
基金funded in part by a grant from the Funding Program for Key Projects for International Cooperation on Science,Technology and Innovation(2020 YFE0205100)Fundamental Scientific Research of Central Public Welfare Foundation from China Academy of China Medical Sciences(YZ-202012)
文摘Background:The global outbreak of coronavirus disease 2019(COVID-19)has brought disastrous consequences to public health and medical systems,whereas no approved medications are currently available.Benefits of traditional Chinese medicine(TCM)against COVID-19 have been observed,however,the underlying mechanistic actions remain unclarified.Due to high pathogenicity and infectivity of the new coronavirus(severe acute respiratory syndrome coronavirus 2[SARS-CoV-2]),the lack of access to SARS-CoV-2 and biosafety level 3(P3)facilities has impeded scientific investigations of TCM against COVID-19.Though low-pathogenic coronavirus and pseudoviral systems have been applied to substitute SARS-CoV-2 in fundamental studies,both models cannot imitate virological and clinical features associated with SARS-CoV-2.The virus-like particle(VLP)is a virological model that is safe and could be performed without biosafety protections.Aims and Objectives:To construct VLP of SARS-CoV-2 containing structural proteins of authentic viruses and resembling the morphology,partial life cycle,and immunoreactions of natural virions,and to introduce VLP into Chinese medical research.Materials and Methods:Using mammalian expression system,we have currently constructed SARS-CoV-2 VLP containing four essential structural proteins.Results:Based on this model,we propose six aspects of research that could be carried out for TCM formulas in the fight against COVID-19.Conclusion:Application of the VLP model provides a safe methodology to strengthen the response systems of Chinese medicine in preventing and controlling newly identified infectious diseases and offers collaborative opportunities for interdisciplinary deciphering of molecular and biological basis of anti-viral TCM formulas.
